Zoledronic acid has recently been shown to significantly reduce the risk of new skeletal related events (SREs) in patients with bone metastases secondary to RCC.

• 唑来膦酸最近已被证明能减少新的骨骼相关事件的危险对于住院的肾癌继发骨转移病人。